Group 1 - The core viewpoint of the article highlights the successful IPO of Jinfang Pharmaceutical-B (02595), with shares priced at HKD 20.39 and a total issuance of 89.24 million shares, raising approximately HKD 1.6699 billion in net proceeds [1] - As of the report, the stock price surged by 128.05%, reaching HKD 46.50, with a trading volume of HKD 651 million [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products, five of which are in clinical development [1] Group 2 - The company’s core products include GFH925, the first KRAS G12C inhibitor approved in China and the third globally, which received approval from the National Medical Products Administration for non-small cell lung cancer (NSCLC) in August 2024 [1] - GFH375 is an oral KRAS G12D inhibitor currently undergoing Phase II clinical trials in China [1] - Jinfang Pharmaceutical has entered into a licensing agreement with Verastem for three candidate products, including GFH375, granting Verastem development and commercialization rights outside Greater China [1]

Group 1 - The core point of the article is that Jinfang Pharmaceutical-B (02595.HK) has seen a significant increase in its stock price, rising nearly 120% as of the report date [1] - During the public offering phase, Jinfang Pharmaceutical-B received a subscription rate of 2,662.79 times, indicating strong investor interest [1] - In the international placement phase, the subscription rate was 39.05 times, further demonstrating robust demand for the company's shares [1]

Group 1 - The core viewpoint of the article highlights the successful listing of Jinfang Pharmaceutical-B (02595) with a share price of HKD 20.39, raising approximately HKD 1.6699 billion from the issuance of 89.24 million shares [1] - As of the report, the stock surged by 115.79%, trading at HKD 44 with a transaction volume of HKD 491 million [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for tumors, autoimmune, and inflammatory diseases, with a product pipeline that includes 8 candidate products, 5 of which are in clinical development [1] Group 2 - GFH925, one of the core products, is the first KRAS G12C inhibitor approved in China and the third globally, having received approval from the National Medical Products Administration for non-small cell lung cancer (NSCLC) in August 2024 [1] - The company is conducting a Phase II trial of GFH925 in the EU under the KORCUS study [1] - GFH375, an oral KRAS G12D inhibitor, is currently undergoing Phase II clinical trials in China, and the company has entered into a licensing agreement with Verastem for GFH375 and two other candidate products, granting Verastem development and commercialization rights outside Greater China [1]

Core Viewpoint - Jinfang Pharmaceutical-B (02595) has successfully listed, with an initial share price of HKD 20.39, raising approximately HKD 1.6699 billion, and has seen a significant increase of 115.79% to HKD 44 per share at the time of reporting [1] Company Overview - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes 8 candidate products, 5 of which are in clinical development [1] - The company has two core products: GFH925 and GFH375 [1] Product Details - GFH925 is the first KRAS G12C inhibitor approved in China and the third globally, having received approval from the National Medical Products Administration for the treatment of non-small cell lung cancer (NSCLC) in August 2024 [1] - GFH375 is an oral KRAS G12D inhibitor currently undergoing Phase II clinical trials in China [1] - Jinfang Pharmaceutical has entered into a licensing agreement with Verastem for three candidate products, including GFH375, granting Verastem development and commercialization rights outside Greater China [1]

Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced a global offering of 89.24 million H-shares at a price of HKD 20.39 per share, with a net proceeds of HKD 1.67 billion [1] Summary by Categories Offering Details - The global offering consists of 89.24 million H-shares, priced at HKD 20.39 each, resulting in net proceeds of HKD 1.67 billion [1] - The Hong Kong public offering accounts for 8.7% of the total shares offered, with a subscription rate of 2,662.79 times [1] - The international offering represents 91.3% of the total shares, with a subscription rate of 39.05 times [1] Trading Information - If the global offering becomes unconditional by September 19, 2025, trading of the H-shares is expected to commence on the Hong Kong Stock Exchange at 9:00 AM [1] - Each board lot for trading H-shares consists of 200 shares, with the stock code being 2595 [1]

Major Events - Jinfang Pharmaceutical-B (02595) received a subscription rate of 2662.79 times for its public offering in Hong Kong, raising approximately HKD 1.67 billion from the global offering [1] - Heng Rui Pharmaceutical (01276) announced that its SHR-1501 injection has been included in the list of proposed breakthrough therapy products [1] - Shanghai Pharmaceuticals (02607) successfully passed the consistency evaluation for the generic drug Nicorandil tablets [1] - Qutech Technology (01478) plans to sell 51.08% of its stake in India for INR 5.53 billion [1] - Boleton (01333) signed a procurement contract for energy storage system equipment with Guoxia Technology [1] - Hongye Futures (03678) shareholders Suhao Huihong and Hongye Logistics collectively reduced their holdings by 5.9482 million shares [1] - Shangu Holdings (00412) responded to concerns about concentrated shareholding, stating that the company can comply with public shareholding regulations [1] - Changfei Optical Fiber and Cable (06869) experienced unusual stock price fluctuations, with its hollow core fiber business not yet significantly impacting financial data [1] - Sanhua Intelligent Control (02050) reported abnormal trading fluctuations in A-shares, confirming no undisclosed significant matters or ongoing major planning [1] Operating Performance - China Pacific Insurance (02601) reported that its life insurance premium income for the first eight months reached CNY 217.05 billion, a year-on-year increase of 13.2% [1] - Datang Renewable (01798) completed a power generation volume of 2.1691 million MWh in August, representing a year-on-year increase of 27.5% [1]

格隆汇9月18日丨劲方医药-B(02595.HK)公告，公司全球发售8924万股H股，每股发售股份20.39港元， 所得款项净额16.7亿港元。香港公开发售股份数目占全球发售股份数目8.7%，获认购2,662.79倍；国际 发售股份数目占全球发售股份91.3%，获认购39.05倍。假设全球发售于2025年9月19日(星期五)上午八时 正(香港时间)或前成为无条件，预期H股将于2025年9月19日(星期五)上午九时正开始在联交所买卖。H 股的每手买卖单位为200股H股，H股的股份代号为2595。 ...

其中，香港公开发售获2662.79倍认购，国际发售获39.05倍认购。 劲方医药-B(02595)公布配发结果，公司全球发售8924万股股份，香港公开发售占8.7%，国际发售占 91.3%。每股发售价20.39港元，全球发售净筹约16.7亿港元。每手200股，预期H股将于2025年9月19日 (星期五)上午九时正开始在联交所买卖。 ...

其中，香港公开发售获2662.79倍认购，国际发售获39.05倍认购。 智通财经APP讯，劲方医药-B(02595)公布配发结果，公司全球发售8924万股股份，香港公开发售占 8.7%，国际发售占91.3%。每股发售价20.39港元，全球发售净筹约16.7亿港元。每手200股，预期H股将 于2025年9月19日(星期五)上午九时正开始在联交所买卖。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本公告全部或任何部分內容而產生或因依賴該等內容引致的任何損失承擔任何責任。 本公告不會直接或間接在或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並非亦無意構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。發售股份不曾亦不會根據1933年美國證券法（經不時修訂）（「美國證券 法」）或美國任何州或其他司法管轄區的證券法登記，且不得在美國境內提呈發售、出售、抵押 或轉讓，惟獲豁免遵守或毋須遵守美國證券法登記規定及任何適用的州證券法的交易除外。發 售股份將不會於美國進行公開發售。發售股份僅可(1)根據美國證券法的登記豁免向合資格機構 買家（定義見美國證券法第144A條）；及(2)根據美國證券法S規例以及進行發售及出售的各司法 管轄區適用法律在美國境外以離岸交易方式提呈發售及出售。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。有意 投資者應先細 ...